MAKING STRIDES TOWARD NEW TREATMENTS

ONE ENDPOINT AT A TIME

Major Depressive Disorder (MDD) is associated with patient suffering and disability around the world. Despite the need, developing new and more effective treatments has been met with repeated challenges. At Signant, we have the expertise, scientific team, experience, global breadth, and innovative technology to help sponsors run successful MDD trials. Leverage our SmartSignals suite to help your adult or pediatric MDD trial succeed.

MANAGE RATER QUALITY TO IMPROVE DATA RELIABILITY

Train and monitor raters to ensure consistency and accuracy with Rater Training and Qualification as well as Central Review services. Our experts ensure raters score/ administer MDD assessments correctly as well as adhere to eligibility criteria and study protocols. We also mitigate excessive placebo response, expectation bias, and provide independent reviews/scoring of diagnostic and efficacy measures.

MONITOR ENDPOINT DATA IN REAL-TIME

Our unique PureSignal Analytics solution leverages proprietary algorithms to evaluate clinical outcome assessment data at all levels in real-time. Expert clinicians analyze outliers, anomalies or discrepancies that could indicate quality risks, and deliver appropriate interventions. By proactively safeguarding endpoint data reliability throughout study lifecycle, the solution helps optimize signal detection.

SIMPLIFY ASSESSMENTS AND ADHERENCE FOR PARTICIPANTS

Patient-reported outcome measures (PROMs) are vital to fully evaluate MDD treatment risk-benefit profiles. Our eCOA solution can be tailored to your protocol and patient population's needs – guided assessments and built-in edit checks reduce errors while alerts and reminders improve adherence to medication dosing schedules.

OPTIMIZE THE PARTICIPANT EDUCATION EXPERIENCE

Signant's robust eConsent platform employs multimedia, managed interactions, content flagging, and virtual visits to ensure participant comprehension of your protocol requirements while improving site and participant experience. Automated version control ensures the presentation of the most recently approved ICD versions, thus eliminating this common FDA audit finding.

MAXIMIZE SIGNAL DETECTION OPPORTUNITIES

Talk through your MDD protocol with our science and medicine experts, who serve as an extension of your study team. We guide the selection and acquisition of endpoints and assessments, advise on inclusion/ exclusion criteria, and recommend methods to decrease site and participant burdens while improving data quality.

Signant's end-to-end suite of evidence generation solutions and accompanying MDD clinical science and medicine expertise reduce burdens for participants and study teams while generating more accurate, reliable data to improve confidence in study outcome conclusions.

SIGNANT'S MAJOR DEPRESSIVE DISORDER CLINICAL TRIAL SOLUTIONS EXPERIENCE

Phases
I II III IV

Привет Ciao

24 Languages

4,400 Sites

24 Countries

9,700 Patients

141 Trials

INSTRUMENTS

SCID | MINI | K-SADS | HAM-D | MADRS | CDRS-R
CGI-S/I | QIDS | PHQ9 | SDS

SMARTSIGNALS SOLUTIONS

The solutions can be used individually or integrated together for a seamless, end-to-end digital experience.

| eCOA | PureSignal Analytics | Advisory | eConsent |

DISCUSS YOUR NEXT STUDY WITH US

Signant's MDD solutions are overseen by a full-time science and medicine team, including:

- Clinical trials methodologists
- eCOA scientists
- Scientific Advisory Board
- International MDD experts

MEET THE EXPERTS